Aerie Pharmaceuticals, a biopharmaceuticals firm which has a major center in Newport Beach, has filed for an IPO, saying in a filing with the SEC that it is looking to raise up to $57.5M on the NASDAQ Global Market. The company says it plans to list as AERI. The IPO is being underwritten by RBC Capital Markets, Stifel, Lazard Capital Markets and Canaccord Genuity. Aerie Pharmaceuticals is venture backed by ACP, Clarus Lifesciences, Sofinnova Venture Partners, TPG Biotech, and others. The company has locations in Bedminster, NJ, Research Triangle Park, N.C., plus Newport Beach. Aerie Pharmaceuticals is focused on developing therapies for the treatment of patients with glaucoma and other diseases of the eye.
Top NewsWednesday, September 18, 2013
Aerie Pharmaceuticals Files For IPO